101. Outcomes of peripheral blood stem cell transplantation patients from HLA-mismatched unrelated donor with antithymocyte globulin (ATG)-Thymoglobulin versus ATG-Fresenius: a single-center study
- Author
-
Shu-Hong Wang, Zhan-Xiang Liu, Xiao-Li Zhao, Yu Jing, Li Yu, Ting-Ting Cao, Ya-Min Tian, Wenrong Huang, Chun-Ji Gao, and Yan-Fen Li
- Subjects
Adult ,Male ,endocrine system ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Graft vs Host Disease ,Hematopoietic stem cell transplantation ,Kaplan-Meier Estimate ,Single Center ,Gastroenterology ,Disease-Free Survival ,Young Adult ,Antibody Specificity ,HLA Antigens ,Internal medicine ,medicine ,Humans ,Young adult ,Adverse effect ,Antilymphocyte Serum ,Retrospective Studies ,Hematology ,Thymoglobulin ,business.industry ,Incidence (epidemiology) ,Incidence ,Hematopoietic Stem Cell Transplantation ,Retrospective cohort study ,General Medicine ,Middle Aged ,Allografts ,Surgery ,Treatment Outcome ,Oncology ,Hematologic Neoplasms ,Histocompatibility ,Female ,business - Abstract
Although antithymocyte globulin (ATG) had been widely used in hematopoietic stem cell transplantation from unrelated donor due to its ability to prevent acute and chronic graft-versus-host disease (GVHD), the comparative efficacy and safety of ATG-Thymoglobulin (ATG-T) and ATG-Fresenius (ATG-F) in patients undergoing HLA-mismatched allogeneic peripheral blood stem cell transplantation from unrelated donors (UR-PBSCT) has not been evaluated. Retrospective analysis of patients who underwent HLA-mismatched UR-PBSCT between January 2003 and December 2013 and received pre-transplant ATG-T at a total dose of 10 mg/kg or ATG-F at a total dose of 20 mg/kg was performed. Patients who received ATG-T (n = 23) or ATG-F (n = 28) had similar baseline demographic, disease, and transplant characteristics. There were no significant between-groups differences in the probability of acute GVHD (P = 0.721) and chronic GVHD (P = 0.439). ATG-F was associated with nonsignificant trends toward higher disease-free survival at 3-year follow-up compared with ATG-T (45.7 ± 11.1 vs 61.3 ± 9.7 %, respectively, P = 0.07). A significantly greater proportion of ATG-T patients experienced high fever than ATG-F patients (P
- Published
- 2014